Allogeneic cell therapy bioprocess economics and optimization: Downstream processing decisions

Regenerative Medicine

Volumn 10, Issue 5, 2015, Pages 591-609

  Hassan, Sally ^a   Simaria, Ana S ^a   Varadaraju, Hemanthram ^b,c   Gupta, Siddharth ^b   Warren, Kim ^b   Farid, Suzanne S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Lonza Walkersville Inc ^*  (United States)

^c Modern Meadow   (United States)

Author keywords

allogeneic cell therapy manufacture; bioprocess economics; centrifugation; downstream processing; filling; tangential flow filtration

Indexed keywords

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BIOFILTRATION; BIOPROCESS; CELL EXPANSION; CENTRIFUGATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOWNSTREAM PROCESSING; FEASIBILITY STUDY; FLUIDIZED BED; FLUIDIZED BED CENTRIFUGATION; FLUIDIZED BED REACTOR; MESENCHYMAL STROMA CELL; PRIORITY JOURNAL; PROCESS OPTIMIZATION; TANGENTIAL FLOW FILTRATION; ALLOTRANSPLANTATION; BIOLOGICAL THERAPY; BIOREACTOR; CELL CULTURE TECHNIQUE; CELL PROLIFERATION; COST BENEFIT ANALYSIS; DECISION MAKING; ECONOMICS; HUMAN; INDUSTRY; PROCEDURES; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION;

BIOREACTORS; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; CELL- AND TISSUE-BASED THERAPY; COST-BENEFIT ANALYSIS; DECISION MAKING; HUMANS; INDUSTRY; MESENCHYMAL STROMAL CELLS; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 84938591550     PISSN: 17460751     EISSN: 1746076X     Source Type: Journal    
DOI: 10.2217/rme.15.29     Document Type: Article

References (20)

1. Smith DM. Assessing commercial opportunities for autologous and allogeneic cell-based products. Regen. Med. 7, 721-732 (2012).
2. Brandenberger R, Burger S, Campbell A, Fong T, Lapinskas E, Rowley JA. Cell therapy bioprocessing. BioProcess Int. 9(Suppl. 1), 30-37 (2011).
3. Kirouac DC, Zandstra PW. The systematic production of cells for cell therapies. Cell Stem Cell 3, 369-381 (2008).
4. Rowley J, Abraham E, Campbell A, Brandwein H, Oh S. Meeting lot-size challenges of manufacturing adherent cells for therapy. BioProcess Int. 10, 16-22 (2012).
5. Simaria AS, Hassan S, Varadaraju H et al. Allogeneic cell therapy bioprocess economics and optimization: single-use cell expansion technologies. Biotechnol. Bioeng. 111(1), 69-83 (2014).
6. US FDA. 21 CFR 610. 15. Code of Federal Regulations, general biological products standards, constituent materials. www. Accessdata. fda. gov/scripts/cdrh
7. Farid SS, Washbrook J, Titchener-Hooker NJ. Decision support tool for assessing biopharmaceutical strategies under uncertainty: stainless steel vs. disposable equipment for clinical trial material preparation. Biotechnol. Progr. 21, 486-497 (2005).
8. Pattasseril J, Varadaraju H, Lock LT, Rowley JA. Downstream technology landscape for large-scale therapeutic cell processing. Bioprocess Int. 11(3), 38-47 (2013).
9. Rowley J, Pattasseril J, Mohamed A. High yield method and apparatus for volume reduction and washing of therapeutic cells using tangential flow filtration. WO 2011091248 A1. (2011).
10. Ksepsytsems. www. ksepsytsems. com
11. Szczypka M, Splan D, Woolls H, Brandwein H. Singleuse bioreactors and microcarriers scalable technology for cell-based therapies. Bioprocess Int. 12(3), 54-64 (2014).
12. ClinicalTrials Database: NCT01663116. https://clinicaltrials. gov/ct2/show/NCT01663116
13. ClinicalTrials Database: NCT00823316. https://clinicaltrials. gov/ct2/show/NCT00823316
14. Malik N . Allogeneic versus autologous stem-cell therapy. Biopharm Int. 25(7), 36-40 (2012).
15. Cooper AR, Patel S, Senadheera S, Plath K, Kohn DB, Hollis RP. Highly efficient large-scale lentiviral vector concentration by tandem tangential flow filtration. J. Virol. Methods 177 1-9 (2011)).
16. Pollock J, Ho SV, Farid SS. Fed-batch and perfusion culture processes: economic, environmental, and operational feasibility under uncertainty, Biotech Bioeng 110, (1) 206-219 (2013).
17. Lowe CR, Lowe AR, Gupta G et al. New developments in affinity chromatography with potential application in the production of biopharmaceuticals. J. Biochem. Biophys. Methods 49, 561-574 (2001).
18. Andrade AVG, Riewaldt J, Wehner R et al. Gamma irradiation preserves immunosuppressive potential and inhibits clonogenic capacity of human bone marrowderived mesenchymal stromal cells. J. Cell Mol. Med. 18(6), 1184-1193 (2014).
19. Wuchter P, Bieback K, Schrezenmeier H, et al. Standardization of Good Manufacturing Practicecompliantproduction of bone marrow-derived human mesenchymal stromal cells forimmunotherapeutic applications. Cytotherapy 17(2), 128-139 (2015).
20. Francois M, Copland IB, Yuan S, et al. Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon gamma licensing. Cytotherapy 14, 147-152 (2012).